Please wait while the formulary information is being retrieved.
PREMARIN (ESTROGENS, CONJUGATED)
- Abnormal uterine bleeding
- Atrophic vaginitis associated with menopause
- Atrophy of vulva
- Dyspareunia due to menopausal vulvovaginal atrophy
- Hypoestrogenism
- Primary ovarian failure
- Vasomotor symptoms associated with menopause
- Advanced prostatic carcinoma
- Atrophic vaginitis associated with menopause
- Atrophy of vulva
- Female hypogonadism
- Hypoestrogenism due to bilateral oophorectomy
- Metastatic breast carcinoma
- Post-menopausal osteoporosis prevention
0.625 mg/gram vaginal cream
- Insert one-half applicatorful (1 gram) by vaginal route once daily cyclically, 3 weeks on and 1 week off
0.3 mg tablet
- 1 tablet (0.3 mg) by oral route once daily
0.45 mg tablet
- 1 tablet (0.45 mg) by oral route once daily
0.625 mg tablet
- 1 tablet (0.625 mg) by oral route once daily
0.9 mg tablet
- 1 tablet (0.9 mg) by oral route once daily
1.25 mg tablet
- 1 tablet (1.25 mg) by oral route once daily
25 mg solution for injection
- Inject 25 mg by intravenous route once ; may repeat in 6-12 hours, ifnecessary
Abnormal uterine bleeding
- Inject 25 mg by intramuscular route once ; may repeat in 6-12 hours, if necessary
- Inject 25 mg by intravenous route once ; may repeat in 6-12 hours, ifnecessary
Advanced prostatic carcinoma
- 1 tablet (1.25 mg) by oral route 3 times per day
- 2 tablets (1.25 mg) by oral route 3 times per day
- 2 tablets (1.8 mg) by oral route 3 times per day
- 2 tablets (2.5 mg) by oral route 3 times per day
Atrophic vaginitis associated with menopause
- 1 tablet (0.3 mg) by oral route once daily
- 1 tablet (0.3 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
- 1 tablet (0.45 mg) by oral route once daily
- Insert one-fourth applicatorful (0.5 gram) by vaginal route once daily cyclically, 3 weeks on and 1 week off
- 1 tablet (0.625 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
- 1 tablet (0.625 mg) by oral route once daily
- 1 tablet (0.9 mg) by oral route once daily
- 1 tablet (0.9 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
- Apply 0.5 gram by topical route once daily cyclically, 3 weeks on and1 week off
- Apply 1 gram by topical route once daily cyclically, 3 weeks on and 1Week off
- Apply 1.5 gram by topical route once daily cyclically, 3 weeks on and1 week off
- Apply 2 gram by topical route once daily cyclically, 3 weeks on and 1Week off
- Insert 0.5 gram by vaginal route once daily cyclically, 3 weeks on and 1 week off
- Insert 1 gram by vaginal route once daily cyclically, 3 weeks on and 1 week off
- Insert 1.5 gram by vaginal route once daily cyclically, 3 weeks on and 1 week off
- Insert 2 gram by vaginal route once daily cyclically, 3 weeks on and 1 week off
- Insert one-half applicatorful (1 gram) by vaginal route once daily cyclically, 3 weeks on and 1 week off
- Insert 1 applicatorful (2 gram) by vaginal route once daily cyclically, 3 weeks on and 1 week off
- 1 tablet (1.25 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
- 1 tablet (1.25 mg) by oral route once daily
- Insert 0.75 applicatorful (1.5 gram) by vaginal route once daily cyclically, 3 weeks on and 1 week off
Atrophy of vulva
- Insert one-fourth applicatorful (0.5 gram) by vaginal route twice weekly
- Insert one-fourth applicatorful (0.5 gram) by vaginal route once daily cyclically, 3 weeks on and 1 week off
- Insert 0.5 gram by vaginal route once daily cyclically, 3 weeks on and 1 week off
- Insert 0.5 gram by vaginal route twice weekly
Dyspareunia due to menopausal vulvovaginal atrophy
- Insert one-fourth applicatorful (0.5 gram) by vaginal route twice weekly
- Insert one-fourth applicatorful (0.5 gram) by vaginal route once daily cyclically, 3 weeks on and 1 week off
- Insert 0.5 gram by vaginal route once daily cyclically, 3 weeks on and 1 week off
- Insert 0.5 gram by vaginal route twice weekly
Female hypogonadism
- 1 tablet (1.25 mg) by oral route 3 times per day for 20 consecutive days, followed by 10 days off
- 1 tablet (1.25 mg) by oral route 2 times per day for 20 consecutive days, followed by 10 days off
- 2 tablets (2.5 mg) by oral route 2 times per day for 20 consecutive days, followed by 10 days off
- 2 tablets (2.5 mg) by oral route 3 times per day for 20 consecutive days, followed by 10 days off
Hypoestrogenism due to bilateral oophorectomy
- 1 tablet (0.3 mg) by oral route once daily
- 1 tablet (0.3 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
- 1 tablet (0.625 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
- 1 tablet (0.625 mg) by oral route once daily
Post-menopausal osteoporosis prevention
- 1 tablet (0.3 mg) by oral route once daily
- 1 tablet (0.45 mg) by oral route once daily
- 1 tablet (0.45 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
- 1 tablet (0.625 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
Primary ovarian failure
- 2 tablets (1.25 mg) by oral route once daily
- 1 tablet (1.25 mg) by oral route once daily cyclically, 3 weeks on and 1 week off
- 1 tablet (1.25 mg) by oral route once daily
- 2 tablets (1.25 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
Vasomotor symptoms associated with menopause
- 1 tablet (0.3 mg) by oral route once daily
- 1 tablet (0.3 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
- 1 tablet (0.45 mg) by oral route once daily
- 1 tablet (0.45 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
- 1 tablet (0.625 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
- 1 tablet (0.625 mg) by oral route once daily
- 1 tablet (0.9 mg) by oral route once daily
- 1 tablet (0.9 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
- 1 tablet (1.25 mg) by oral route once daily for 21 consecutive days, followed by 7 days off
- 1 tablet (1.25 mg) by oral route once daily
- anastrozole
- Arimidex
- Aromasin
- Cyklokapron
- exemestane
- Femara
- letrozole
- Lysteda
- tranexamic acid
Contraindicated
- None
Severe
Moderate
- A-hydrocort
- A-methapred
- Alagesic Lq
- amobarbital
- Amytal
- Anucort-hc
- Anusol-hc
- Aristospan Intra-articular
- Aristospan Intralesional
- Ascomp With Codeine
- Belladonna-phenobarbital
- betamethasone acet & sod phos
- Bivigam
- Brevital
- budesonide
- Bupap
- butabarbital
- Butalbital Compound W/codeine
- Butalbital Compound-codeine
- butalbital-acetaminop-caf-cod
- butalbital-acetaminophen
- butalbital-acetaminophen-caff
- butalbital-aspirin-caffeine
- Butisol
- Capacet
- Carimune Nf Nanofiltered
- Celestone Soluspan
- Cerebyx
- codeine-butalbital-ASA-caff
- Colocort
- Cortef
- Cortenema
- Cortifoam
- cortisone
- Depo-medrol
- dexamethasone
- Dexamethasone Intensol
- dexamethasone sodium phos (PF)
- dexamethasone sodium phosphate
- Dexpak 10 Day
- Dexpak 13 Day
- Dexpak 6 Day
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Donnatal
- Entocort Ec
- Esgic
- ethotoin
- Evista
- Ez Use Joint-tunnel-trigger
- Fioricet
- Fioricet With Codeine
- Fiorinal
- Fiorinal-codeine #3
- First-duke's
- First-mary's Mouthwash
- Flebogamma Dif
- Flo-pred
- fludrocortisone
- fosphenytoin
- Gamastan S/d
- Gammagard Liquid
- Gammagard S-d (iga < 1 Mcg/ml)
- Gammagard S/d
- Gammaked
- Gammaplex
- Gamunex-c
- Grx Hicort 25
- Hemril-30
- Hizentra
- hydrocortisone
- hydrocortisone acetate
- hydrocortisone sod succ (PF)
- hydrocortisone sod succinate
- immune glob(IgG)(hum)-maltose
- immune globulin (human) (IgG)
- immune globulin(hum),capr(IgG)
- Kenalog
- Luminal
- Margesic
- Marten-tab
- Medrol
- Medrol (pak)
- methohexital
- methylprednisolone
- methylprednisolone acetate
- methylprednisolone sod suc(PF)
- methylprednisolone sodium succ
- methylprednisolone-bupivacaine
- Millipred
- Millipred Dp
- Mysoline
- Nembutal Sodium
- nystatin-hydrocortisone-diphen
- nystatin-TCN-HC-diphenhydramin
- Octagam
- Orapred
- Orapred Odt
- Pediapred
- Peganone
- pentobarbital sodium
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- Physicians Ez Use M-pred
- prednisolone
- prednisolone acetate
- prednisolone sodium phosphate
- prednisone
- Prednisone Intensol
- primidone
- Privigen
- Proctocort
- raloxifene
- Rayos
- Rectacort-hc
- secobarbital sodium
- Seconal Sodium
- Solu-cortef
- Solu-cortef (pf)
- Solu-medrol
- Solu-medrol (pf)
- Tencon
- triamcinolone acetonide
- triamcinolone hexacetonide
- triamcinolone-lidocaine
- Uceris
- Veripred 20
- Zebutal
- Acute myocardial infarction
- Antithrombin III deficiency
- Carcinoma of breast
- Cerebrovascular accident
- Deep venous thrombosis
- Disease of liver
- Estrogen-dependent neoplasm
- Predisposition to thrombosis
- Protein C deficiency disease
- Pulmonary thromboembolism
- Thromboembolic disorder
- Thrombophilia
Contraindicated
- Bed-ridden
- Carcinoma of breast
- Coronary artery disease
- Dementia
- Endometrial carcinoma
- Estrogen-dependent neoplasm
- Family history of malignant tumor of breast
- Hepatic porphyria
- Hereditary angioedema
- Hypercalcemia
- Increased cardiovascular event risk
- Invasive surgical procedure
- Malignant neoplasm of the ovary
- Mammography abnormal
- Neoplasm of female genital organ
- Papilledema
- Retinal thrombosis
- Tobacco smoker
Severe
Moderate
- Asthma
- Diabetes mellitus
- Edema
- Endometriosis
- Gallbladder disease
- Hepatic porphyria
- Hypertension
- Hypertriglyceridemia
- Hypoparathyroidism
- Hypothyroidism
- Migraine
- Seizure disorder
- Systemic lupus erythematosus
- Tobacco smoker
- Unspecified lump in breast
- Uterine leiomyoma
PREMARIN (ESTROGENS, CONJUGATED)
- Abnormal uterine bleeding
- Atrophic vaginitis associated with menopause
- Atrophy of vulva
- Dyspareunia due to menopausal vulvovaginal atrophy
- Hypoestrogenism
- Primary ovarian failure
- Vasomotor symptoms associated with menopause
- Advanced prostatic carcinoma
- Atrophic vaginitis associated with menopause
- Atrophy of vulva
- Female hypogonadism
- Hypoestrogenism due to bilateral oophorectomy
- Metastatic breast carcinoma
- Post-menopausal osteoporosis prevention
- Gynecomastia
- Mastalgia
- Abdominal distension
- Acute abdominal pain
- Back pain
- Headache disorder
- Infection
- Mastalgia
- Vulvovaginal candidiasis
- Weight gain
More Frequent
Severe
Less Severe
- Back pain
- Gastroenteritis
- Weight gain
- Acne vulgaris
- Arthralgias
- Body fluid retention
- Candidiasis
- Constipation
- Cramps
- Cramps in legs
- Diarrhea
- Dizziness
- Dysmenorrhea
- Flatulence
- General weakness
- Gynecomastia
- Increased appetite
- Insomnia
- Libido changes
- Migraine
- Myalgias
- Nausea
- Pelvic pain
- Peripheral edema
- Pruritus of skin
- Symptoms of anxiety
- Vaginal discharge
- Vaginitis
- Vulvovaginal candidiasis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal vaginal bleeding
- Acute myocardial infarction
- Acute pancreatitis
- Amenorrhea
- Anaphylaxis
- Angioedema
- Asthma exacerbation
- Cerebrovascular accident
- Deep venous thrombosis
- Dementia
- Depression
- Endometrial carcinoma
- Endometrial hyperplasia
- Erythema multiforme
- Erythema nodosum
- Gallbladder obstruction
- Hepatitis
- Hypercalcemia
- Hypersensitivity drug reaction
- Hypertension
- Hypertriglyceridemia
- Hypotension
- Influenza
- Involuntary muscle movement
- Ischemic colitis
- Lower seizure threshold
- Malignant neoplasm of the ovary
- Menorrhagia
- Neoplasm of breast
- Nipple discharge
- Precocious puberty
- Pulmonary thromboembolism
- Retinal thrombosis
- Skin rash
- Thromboembolic disorder
- Thrombophlebitis
- Unspecified lump in breast
- Upper respiratory infection
- Urticaria
- Uterine leiomyoma
- Venous thrombosis
Less Severe
- Abdominal pain with cramps
- Abnormal vaginal bleeding
- Alopecia
- Body fluid retention
- Chloasma
- Depression
- Diarrhea
- Dysmenorrhea
- Genital organ pruritus
- Hirsutism
- Hypertriglyceridemia
- Insomnia
- Keratoconus
- Libido changes
- Mood changes
- Nervousness
- Nipple discharge
- Pelvic pain
- Pruritus of skin
- Urticaria
- Vaginal discharge
- Vaginal irritation
- Vomiting
- Weight loss
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Estrogens, Conjugated
May cause premature epiphyseal closure. Limited information for inducing puberty. Monitor growth in patient with bone immaturity.
Not indicated in pediatrics.
- 1 Day – 18 Years
- May cause premature epiphyseal closure. Limited information for inducing puberty. Monitor growth in patient with bone immaturity.
Estrogens, Vaginal
May cause premature epiphyseal closure. Limited information for inducing puberty. Monitor growth in patient with bone immaturity.
Not indicated in pediatrics.
- 1 Day – 18 Years
- Not indicated in pediatrics.
Estrogens, Conjugated
- Severity Level:
2
- Additional Notes: Not indicated during pregnancy, no known dev tox
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Estrogen, Conjugated (vag)
Mfr does not rec. systemic form can affect quantity & quality of breast milk.
May decrease quantity and quality of breastmilk.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Mfr does not rec. systemic form can affect quantity & quality of breast milk. |
Estrogens, Conjugated (oral, Inj)
Mfr does not rec. systemic form can affect quantity & quality of breast milk.
May decrease quantity and quality of breastmilk.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | May decrease quantity and quality of breastmilk. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Estrogenic Agents (systemic)
General-Use lowest possible dose for shortest duration and in combination with a progestin as indicated to reduce the risk of endometrial hyperplasia and breast cancer. Cardiovascular-May increase risk for thromboembolic events. Avoid use in patients with known, suspected, or history of arterial or venous thromboembolic disease. Neuro/Psych-May increase the risk for dementia. Genitourinary-May aggravate urinary incontinence.
General-Use lowest possible dose for shortest duration and in combination with a progestin as indicated to reduce the risk of endometrial hyperplasia and breast cancer. Low-dose intravaginal estrogen may be used for management of vaginal symptoms (e.g. dyspareunia, recurrent UTIs). Cardiovascular-Avoid with active or history of DVT,PE or thromboembolic disease.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
Estrogenic Agents (vaginal)
General-Use lowest possible dose for shortest duration and in combination with a progestin as indicated to reduce the risk of endometrial hyperplasia and breast cancer. Cardiovascular-May increase risk for thromboembolic events. Avoid use in patients with known, suspected, or history of arterial or venous thromboembolic disease. Neuro/Psych-May increase the risk for dementia. Genitourinary-May aggravate urinary incontinence.
General-Use lowest possible dose for shortest duration and in combination with a progestin as indicated to reduce the risk of endometrial hyperplasia and breast cancer. Low-dose intravaginal estrogen may be used for management of vaginal symptoms (e.g. dyspareunia, recurrent UTIs). Cardiovascular-Avoid with active or history of DVT,PE or thromboembolic disease.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Estrogens, either used alone or with another hormone (progestin), have rarely caused very serious side effects. Discuss the risks and benefits of hormone treatment with your doctor. Estrogens should not be used to prevent heart disease or dementia.<br /><br /> Estrogens can increase the risk of cancer of the uterus (endometrial cancer). Taking a progestin as directed by your doctor can help decrease this risk. Tell your doctor right away if you have any unusual vaginal bleeding.<br /><br /> In postmenopausal women, estrogens can increase the risk of cancer of the ovaries, stroke, dementia, and serious blood clots in the legs. Estrogens alone do not appear to increase the risk of breast cancer when used for up to 7 years. Estrogen, when used with a progestin, can increase the risk of heart disease (such as heart attacks), stroke, serious blood clots in the lungs/legs, dementia, and cancer of the breast/ovaries.<br /><br /> The risk for serious side effects may depend on the dose of estrogen and the length of time it is used. Therefore, this medication should be used at the lowest effective dose and for the shortest amount of time. Discuss the use of this medication with your doctor and check with him/her regularly (for example, every 3 to 6 months) to see if you still need to take this medication.<br /><br />If you will be taking this medication long-term, you should have regular complete physical exams (for example, once a year) as directed by your doctor. See also Notes section.
| Abnormal uterine bleeding | |
| N92 | Excessive, frequent and irregular menstruation |
| N92.0 | Excessive and frequent menstruation with regular cycle |
| N92.1 | Excessive and frequent menstruation with irregular cycle |
| N92.2 | Excessive menstruation at puberty |
| N92.3 | Ovulation bleeding |
| N92.4 | Excessive bleeding in the premenopausal period |
| N92.5 | Other specified irregular menstruation |
| N92.6 | Irregular menstruation, unspecified |
| N93 | Other abnormal uterine and vaginal bleeding |
| N93.0 | Postcoital and contact bleeding |
| N93.8 | Other specified abnormal uterine and vaginal bleeding |
| N93.9 | Abnormal uterine and vaginal bleeding, unspecified |
| Advanced prostatic carcinoma | |
| C61 | Malignant neoplasm of prostate |
| Atrophic vaginitis associated with menopause | |
| N95.2 | Postmenopausal atrophic vaginitis |
| Atrophy of vulva | |
| N90.5 | Atrophy of vulva |
| Dyspareunia due to menopausal vulvovaginal atrophy | |
| N95.2 | Postmenopausal atrophic vaginitis |
| Female hypogonadism | |
| E28.39 | Other primary ovarian failure |
| Hypoestrogenism | |
| E28.3 | Primary ovarian failure |
| E28.31 | Premature menopause |
| E28.310 | Symptomatic premature menopause |
| E28.319 | Asymptomatic premature menopause |
| E28.39 | Other primary ovarian failure |
| E89.4 | Postprocedural ovarian failure |
| E89.40 | Asymptomatic postprocedural ovarian failure |
| E89.41 | Symptomatic postprocedural ovarian failure |
| Hypoestrogenism due to bilateral oophorectomy | |
| E89.4 | Postprocedural ovarian failure |
| E89.40 | Asymptomatic postprocedural ovarian failure |
| E89.41 | Symptomatic postprocedural ovarian failure |
| Metastatic breast carcinoma | |
| C50 | Malignant neoplasm of breast |
| C50.1 | Malignant neoplasm of central portion of breast |
| C50.11 | Malignant neoplasm of central portion of breast, female |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.12 | Malignant neoplasm of central portion of breast, male |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.122 | Malignant neoplasm of central portion of left male breast |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast |
| C50.2 | Malignant neoplasm of upper-inner quadrant of breast |
| C50.21 | Malignant neoplasm of upper-inner quadrant of breast, female |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast |
| C50.22 | Malignant neoplasm of upper-inner quadrant of breast, male |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast |
| C50.3 | Malignant neoplasm of lower-inner quadrant of breast |
| C50.31 | Malignant neoplasm of lower-inner quadrant of breast, female |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast |
| C50.32 | Malignant neoplasm of lower-inner quadrant of breast, male |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast |
| C50.4 | Malignant neoplasm of upper-outer quadrant of breast |
| C50.41 | Malignant neoplasm of upper-outer quadrant of breast, female |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast |
| C50.42 | Malignant neoplasm of upper-outer quadrant of breast, male |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast |
| C50.5 | Malignant neoplasm of lower-outer quadrant of breast |
| C50.51 | Malignant neoplasm of lower-outer quadrant of breast, female |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast |
| C50.52 | Malignant neoplasm of lower-outer quadrant of breast, male |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast |
| C50.529 | Malignant neoplasm of lower-outer quadrant of unspecified male breast |
| C50.6 | Malignant neoplasm of axillary tail of breast |
| C50.61 | Malignant neoplasm of axillary tail of breast, female |
| C50.611 | Malignant neoplasm of axillary tail of right female breast |
| C50.612 | Malignant neoplasm of axillary tail of left female breast |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast |
| C50.62 | Malignant neoplasm of axillary tail of breast, male |
| C50.621 | Malignant neoplasm of axillary tail of right male breast |
| C50.622 | Malignant neoplasm of axillary tail of left male breast |
| C50.629 | Malignant neoplasm of axillary tail of unspecified male breast |
| C50.8 | Malignant neoplasm of overlapping sites of breast |
| C50.81 | Malignant neoplasm of overlapping sites of breast, female |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast |
| C50.819 | Malignant neoplasm of overlapping sites of unspecified female breast |
| C50.82 | Malignant neoplasm of overlapping sites of breast, male |
| C50.821 | Malignant neoplasm of overlapping sites of right male breast |
| C50.822 | Malignant neoplasm of overlapping sites of left male breast |
| C50.829 | Malignant neoplasm of overlapping sites of unspecified male breast |
| C50.9 | Malignant neoplasm of breast of unspecified site |
| C50.91 | Malignant neoplasm of breast of unspecified site, female |
| C50.911 | Malignant neoplasm of unspecified site of right female breast |
| C50.912 | Malignant neoplasm of unspecified site of left female breast |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast |
| C50.92 | Malignant neoplasm of breast of unspecified site, male |
| C50.921 | Malignant neoplasm of unspecified site of right male breast |
| C50.922 | Malignant neoplasm of unspecified site of left male breast |
| C50.929 | Malignant neoplasm of unspecified site of unspecified male breast |
| Post-menopausal osteoporosis prevention | |
| Z78.0 | Asymptomatic menopausal state |
| Primary ovarian failure | |
| E28.3 | Primary ovarian failure |
| E28.31 | Premature menopause |
| E28.310 | Symptomatic premature menopause |
| E28.319 | Asymptomatic premature menopause |
| E28.39 | Other primary ovarian failure |
| Vasomotor symptoms associated with menopause | |
| N95.1 | Menopausal and female climacteric states |
| N95.9 | Unspecified menopausal and perimenopausal disorder |
| 0-9 | A-Z |
|---|---|
| C50 | Malignant neoplasm of breast |
| C50.1 | Malignant neoplasm of central portion of breast |
| C50.11 | Malignant neoplasm of central portion of breast, female |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.12 | Malignant neoplasm of central portion of breast, male |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.122 | Malignant neoplasm of central portion of left male breast |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast |
| C50.2 | Malignant neoplasm of upper-inner quadrant of breast |
| C50.21 | Malignant neoplasm of upper-inner quadrant of breast, female |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast |
| C50.22 | Malignant neoplasm of upper-inner quadrant of breast, male |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast |
| C50.3 | Malignant neoplasm of lower-inner quadrant of breast |
| C50.31 | Malignant neoplasm of lower-inner quadrant of breast, female |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast |
| C50.32 | Malignant neoplasm of lower-inner quadrant of breast, male |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast |
| C50.4 | Malignant neoplasm of upper-outer quadrant of breast |
| C50.41 | Malignant neoplasm of upper-outer quadrant of breast, female |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast |
| C50.42 | Malignant neoplasm of upper-outer quadrant of breast, male |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast |
| C50.5 | Malignant neoplasm of lower-outer quadrant of breast |
| C50.51 | Malignant neoplasm of lower-outer quadrant of breast, female |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast |
| C50.52 | Malignant neoplasm of lower-outer quadrant of breast, male |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast |
| C50.529 | Malignant neoplasm of lower-outer quadrant of unspecified male breast |
| C50.6 | Malignant neoplasm of axillary tail of breast |
| C50.61 | Malignant neoplasm of axillary tail of breast, female |
| C50.611 | Malignant neoplasm of axillary tail of right female breast |
| C50.612 | Malignant neoplasm of axillary tail of left female breast |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast |
| C50.62 | Malignant neoplasm of axillary tail of breast, male |
| C50.621 | Malignant neoplasm of axillary tail of right male breast |
| C50.622 | Malignant neoplasm of axillary tail of left male breast |
| C50.629 | Malignant neoplasm of axillary tail of unspecified male breast |
| C50.8 | Malignant neoplasm of overlapping sites of breast |
| C50.81 | Malignant neoplasm of overlapping sites of breast, female |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast |
| C50.819 | Malignant neoplasm of overlapping sites of unspecified female breast |
| C50.82 | Malignant neoplasm of overlapping sites of breast, male |
| C50.821 | Malignant neoplasm of overlapping sites of right male breast |
| C50.822 | Malignant neoplasm of overlapping sites of left male breast |
| C50.829 | Malignant neoplasm of overlapping sites of unspecified male breast |
| C50.9 | Malignant neoplasm of breast of unspecified site |
| C50.91 | Malignant neoplasm of breast of unspecified site, female |
| C50.911 | Malignant neoplasm of unspecified site of right female breast |
| C50.912 | Malignant neoplasm of unspecified site of left female breast |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast |
| C50.92 | Malignant neoplasm of breast of unspecified site, male |
| C50.921 | Malignant neoplasm of unspecified site of right male breast |
| C50.922 | Malignant neoplasm of unspecified site of left male breast |
| C50.929 | Malignant neoplasm of unspecified site of unspecified male breast |
| C61 | Malignant neoplasm of prostate |
| E28.3 | Primary ovarian failure |
| E28.3 | Primary ovarian failure |
| E28.31 | Premature menopause |
| E28.31 | Premature menopause |
| E28.310 | Symptomatic premature menopause |
| E28.310 | Symptomatic premature menopause |
| E28.319 | Asymptomatic premature menopause |
| E28.319 | Asymptomatic premature menopause |
| E28.39 | Other primary ovarian failure |
| E28.39 | Other primary ovarian failure |
| E28.39 | Other primary ovarian failure |
| E89.4 | Postprocedural ovarian failure |
| E89.4 | Postprocedural ovarian failure |
| E89.40 | Asymptomatic postprocedural ovarian failure |
| E89.40 | Asymptomatic postprocedural ovarian failure |
| E89.41 | Symptomatic postprocedural ovarian failure |
| E89.41 | Symptomatic postprocedural ovarian failure |
| N90.5 | Atrophy of vulva |
| N92 | Excessive, frequent and irregular menstruation |
| N92.0 | Excessive and frequent menstruation with regular cycle |
| N92.1 | Excessive and frequent menstruation with irregular cycle |
| N92.2 | Excessive menstruation at puberty |
| N92.3 | Ovulation bleeding |
| N92.4 | Excessive bleeding in the premenopausal period |
| N92.5 | Other specified irregular menstruation |
| N92.6 | Irregular menstruation, unspecified |
| N93 | Other abnormal uterine and vaginal bleeding |
| N93.0 | Postcoital and contact bleeding |
| N93.8 | Other specified abnormal uterine and vaginal bleeding |
| N93.9 | Abnormal uterine and vaginal bleeding, unspecified |
| N95.1 | Menopausal and female climacteric states |
| N95.2 | Postmenopausal atrophic vaginitis |
| N95.2 | Postmenopausal atrophic vaginitis |
| N95.9 | Unspecified menopausal and perimenopausal disorder |
| Z78.0 | Asymptomatic menopausal state |
Formulary Reference Tool